Freeline appoints Julia P Gregory to its Board of Directors

An experienced biopharmaceutical executive with more than 20 years of investment banking experience.

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julia P Gregory, to its Board of Directors. Ms. Gregory is a seasoned biopharmaceutical executive with CEO, CFO, Corporate Development, Board and Investment Banking experience.

“We are delighted to welcome Julia to Freeline’s Board of Directors,” said Chris Hollowood, Executive Chairman of Freeline. “She brings significant experience in biopharma governance, operations and investment banking. I look forward to working with her as we build the Company and progress our innovative gene therapy programmes through the clinic and towards commercialisation.”

“I am very pleased to be joining Freeline at this exciting time as the company brings curative gene therapies to patients suffering from the likes of Hemophilia, Fabry disease and Gaucher disease,” said Julia Gregory. “I look forward to working with the Board and management team to realise the full potential of these transformative therapies.”

Currently Chair and CEO of Isometry Advisors, Inc., a biotechnology advisory company, Ms. Gregory also serves as a non-executive director of several biopharmaceutical companies, including Biohaven Therapeutics, Cell Medica, Iconic Therapeutics, IMV, Nurix Therapeutics, and Sosei-Heptares. She is also a senior advisor to the Morgan Stanley’s Private Equity Growth Fund and M. M. Dillon & Co., Inc.

In her previous executive roles, Ms. Gregory served as Chief Executive Officer, Chief Financial Officer and Board Director of ContraFect Corporation; President and CEO of Five Prime Therapeutics; and Executive Vice President, Corporate Development and Chief Financial Officer of Lexicon Pharmaceuticals, Inc. Her corporate development experience includes leading transactions for significant strategic partnerships including development and licensing agreements with GlaxoSmithKline, Human Genome Sciences, Genentech, Bristol-Myers Squibb Company and Takeda Pharmaceutical Company Limited. As CFO at Lexicon, she led the company’s $220 million public offering and was involved in the creation of Lexicon’s $500 million private equity plan with Invus, LLP. Prior to her leadership positions in the biopharmaceutical industry, Ms. Gregory was an investment banker at Dillon, Read & Co. and subsequently at Punk, Ziegel & Company, where she served as the head of investment banking and head of its life sciences practice.

She received her B.A. in International Affairs from George Washington University ‘s Elliot School of International Affairs where she was elected to Phi Beta Kappa and her M.B.A. from The Wharton School of The University of Pennsylvania.

Back to News and insights